

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following best describes the mechanism of action of the novel agent relatlimab?
  - Anti-PD-1/PD-L1 antibody
  - Anti-LAG3 antibody
  - Bispecific HER2-targeting antibody
  - Claudin 18.2-targeting monoclonal antibody
  - TROP2-directed antibody-drug conjugate
- Primary results from the Phase II DESTINY-CRC02 study evaluating 2 doses of trastuzumab deruxtecan (T-DXd) for patients with HER2-overexpressing/amplified metastatic colorectal cancer (mCRC), which showed promising antitumor activity with T-DXd at both 5.4 mg/kg and 6.4 mg/kg doses, established which dose as the optimal single-agent dose in this patient population because of its positive risk-benefit profile?
  - 5.4 mg/kg
  - 6.4 mg/kg
  - Neither 5.4 mg/kg nor 6.4 mg/kg
- In the CIRCULATE-Japan study, which outcome was observed regarding disease-free survival (DFS) and circulating tumor DNA (ctDNA) dynamics?
  - Sustained ctDNA clearance was associated with superior DFS, and the DFS benefit was maintained at 24 months
  - Transient ctDNA clearance was associated with improved DFS, and the DFS benefit was sustained at 24 months
  - No difference in DFS was observed between patients with sustained and transient ctDNA clearance
- What was the approximate objective response rate reported with tucatinib/trastuzumab for patients with chemo-refractory HER2-positive mCRC in the Phase II MOUNTAINEER study?
  - 3%
  - 15%
  - 38%
  - 66%
- What was the approximate reduction in risk of disease progression or death with first-line nivolumab/ipilimumab compared to chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient mCRC in the Phase III CheckMate 8HW trial?
  - 19%
  - 39%
  - 59%
  - 79%